文献速递艾滋病与性传播感染结核与非结核分枝杆菌

调整剂量8小时给药洛匹那韦/利托那韦在合并利福平治疗的HIV感染儿童中的药代动力学

Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

这项前瞻性药代动力学研究纳入11名接受利福平治疗的HIV感染儿童,将标准二线洛匹那韦/利托那韦方案转换为按体重分带的8小时给药方案。结果显示仅63.6%的儿童洛匹那韦Cmin≥1 mg/L,且洛匹那韦mg/kg剂量低于中位数21.5与Cmin<1 mg/L相关(P=0.02),不支持所研究剂量的8小时给药策略。

要点

  • 8小时给药洛匹那韦/利托那韦仅63.6%儿童Cmin达标。
  • 洛匹那韦剂量低于21.5 mg/kg与Cmin<1 mg/L相关(P=0.02)。
  • 需评估更高剂量以优化儿童TB/HIV治疗。

核心结论

  • 所研究的8小时洛匹那韦/利托那韦剂量方案不推荐用于合并利福平治疗的HIV感染儿童。
  • 需要评估更高剂量以优化结核与HIV合并感染幼儿的治疗结局。

研究设计与样本

  • 前瞻性药代动力学研究,纳入11名接受洛匹那韦/利托那韦和利福平治疗的HIV感染儿童。
  • 儿童从标准二线洛匹那韦/利托那韦4:1加用利托那韦(1:1比例)每日两次,转换为按体重分带的8小时洛匹那韦/利托那韦4:1给药。
  • 利福平剂量为10-20 mg/kg/天;2周后采集早晨给药后约2、4、6、8和10小时的血浆样本。

主要发现

  • 11名儿童中7名(63.6%)洛匹那韦Cmin≥1 mg/L,中位Cmin为3.0 mg/L(IQR 0.1-5.5)。
  • 洛匹那韦mg/kg剂量低于中位数21.5的儿童更可能出现Cmin<1 mg/L(P=0.02)。
  • 洛匹那韦与利托那韦浓度呈强正相关。
  • 洛匹那韦AUC2-10与年龄、性别、体重、营养状态或洛匹那韦mg/kg剂量无关联。

关键数值与推荐

  • 洛匹那韦Cmin目标值≥1 mg/L。
  • 5名(45%)儿童体重10-13.9 kg,接受洛匹那韦20-24 mg/kg/剂;6名(55%)儿童体重6-9.9 kg,接受洛匹那韦20-23 mg/kg/剂。
  • 中位年龄15个月(IQR 12.6-28.8个月)。

临床怎么用

  • 在合并利福平治疗的HIV感染幼儿中,不应常规使用所研究的8小时洛匹那韦/利托那韦剂量方案。
  • 需关注洛匹那韦mg/kg剂量低于21.5时Cmin不达标风险增高。

局限性

  • 样本量小(11名儿童),仅两个体重带。
  • 未评估更高剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the proportion of children with lopinavir Cmin ≥1 mg/L when receiving a novel 8-hourly lopinavir/ritonavir dosing strategy during rifampicin co-treatment. METHODS: HIV-infected children on lopinavir/ritonavir and rifampicin were enrolled in a prospective pharmacokinetic study. Children were switched from standard-of-care lopinavir/ritonavir-4:1 with additional ritonavir (1:1 ratio) twice daily to 8-hourly lopinavir/ritonavir-4:1 using weight-banded dosing. Rifampicin was dosed at 10-20 mg/kg/day. After 2 weeks, plasma samples were collected ∼2, 4, 6, 8 and 10 h after the morning lopinavir/ritonavir-4:1 dose, ALT was obtained to assess safety and treatment was switched back to standard of care. ClinicalTrials.gov registration number: NCT01637558. RESULTS: We recruited 11 children in two weight bands: 5 (45%) were 10-13.9 kg and received 20-24 mg/kg/dose of lopinavir and 6 (55%) children weighed 6-9.9 kg and received 20-23 mg/kg/dose of lopinavir. The median age was 15 months (IQR = 12.6-28.8 months). The median (IQR) lopinavir Cmin was 3.0 (0.1-5.5) mg/L. Seven (63.6%) of the 11 children had Cmin values ≥1 mg/L. Children with a lopinavir mg/kg dose below the median 21.5 were more likely to have Cmin <1 mg/L (P = 0.02). There was a strong positive correlation between lopinavir and ritonavir concentrations. No associations were found between lopinavir AUC2-10 and age, sex, weight, nutritional status or mg/kg/dose of lopinavir. CONCLUSIONS: These data do not support the use of 8-hourly lopinavir/ritonavir at studied doses. Evaluation of higher doses is needed to optimize treatment outcomes of TB and HIV in young children.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rabie H, Rawizza H, Zuidewind P, et al. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. J Antimicrob Chemother. 2019. PMID: 31081020. doi:10.1093/jac/dkz171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。